Technology transfer: the hidden bottleneck in pharmaceutical value realisation

Tech transfer is often treated as an IT problem, not a knowledge workflow. Fixing the R&D-to-manufacturing data mismatch using shared, interoperable data — not unified systems — could unlock faster, cheaper drug delivery

You need to be a subscriber to read this article.
Click here to find out more.

A molecule rarely travels in a straight line. The chemistry is defined in one place, scaled in another, manufactured in a third and finished in a fourth … and at every handoff the knowledge that made it work is supposed to travel with it.

Technology transfer: the hidden bottleneck in pharmaceutical value realisation

But too often that data is inaccessible because the work achieved during previous stages is not inherited digitally.

Data is repeatedly deconstructed, reconfigured and rebuilt. Processes end up being redeveloped from scratch.

The result is rework at scale that adds complexity and delays time to market.

This, however, is not simply a technology issue. This is a problem of accessible knowledge flow.

Rob Innes, Director of Data and AI at DTG, reports. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like